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Background: SCALOP, a randomised, phase II trial, tested the activity and safety of gemcitabine (GEM)-based and capecitabine
(CAP)-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Here we present the long-term outcomes.
Methods: Eligibility: histologically proven LAPC p7 cm. Following 12 weeks of induction GEMCAP chemotherapy (three cycles:
GEM 1000mgm 2 days 1, 8, 15; CAP 830mgm 2 days 1–21 q28 days) patients with stable/responding disease, tumour p6 cm,
and WHO Performance Status 0–1 were randomised to receive one cycle GEMCAP followed by CAP (830mgm 2 b.d. on
weekdays only) or GEM (300mgm 2 weekly) with radiation (50.4Gy per 28 fractions).
Results:One-hundred fourteen patients (28 UK centres) were registered between 24 December 2009 and 25 October 2011, and 74
were randomised (CAP-RT¼ 36; GEM-RT¼ 38). At the time of this analysis, 105 of the 114 patients had died and the surviving 9
patients had been followed up for a median of 10.9 months (IQR: 2.9–18.7). Updated median OS was 17.6 months (95% CI: 14.6–
22.7) in the CAP-CRT arm and 14.6 months (95% CI: 11.1–16.0) in the GEM-CRT arm (intention-to-treat adjusted hazard ratio (HR):
0.68 (95% CI: 0.38–1.21, P¼ 0.185)); median progression-free survival (PFS) was 12.0 months (95% CI: 10.0–15.2) in the CAP-CRT arm
and 10.4 months (95% CI: 8.8–12.7) in the GEM-CRT arm (intention-to-treat adjusted HR: 0.60 (95% CI: 0.32–1.14, P¼ 0.120)). In
baseline multivariable model, age X65 years, better performance status, CA19.9o613 IU l 1, and shorter tumour diameter
predicted improved OS. CAP-CRT, age X65 years, better performance status, CA19.9 o46 IUml 1 predicted improved OS and
PFS in the pre-radiotherapy model. Nine-month PFS was highly predictive of OS.
Conclusions: CAP-CRT remains the superior regimen. SCALOP showed that patients with CA19.9 o46 IUml 1 after induction
chemotherapy are more likely to benefit from CRT.
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The SCALOP trial (Selective Chemoradiation in Advanced
Localised Pancreatic Cancer) was a randomised multicentre, phase
II, open-label trial of GEM-CRT vs CAP-CRT following four cycles
of GEMCAP chemotherapy in LAPC. It was developed to assess
the activity, safety and feasibility of delivering high-quality
pancreatic CRT across multiple centres in the UK and to determine
the relative benefits and toxicity of gemcitabine vs capecitabine as
concurrent chemotherapy. To date, this is one of the largest trials
testing the approach of induction chemotherapy followed by
consolidation CRT and the trial results were reported after the
primary end-point (9-month progression-free survival (PFS)) was
reached (Mukherjee et al, 2013). The 9-month PFS was 62.9%
(80% CIs: 50.6–73.9%, n¼ 35) in the CAP-CRT arm and 51.4%
(80% CIs: 39.4–63.4%, n¼ 35) in the GEM-CRT arm (median PFS
12.0 vs 10.4 months, hazard ratio (HR)¼ 0  60, P¼ 0  11) and the
OS was reported to be significantly superior in the CAP-CRT arm
(median OS 15.2 vs 13.4 months, HR¼ 0.39, P¼ 0.012). More
patients in the GEM-CRT arm experienced grade 3/4 haematolo-
gical (18.4% vs 0%, P¼ 0.008) and non-haematological (26.3% vs
11.8%, P¼ 0.12) toxicities during CRT. The quality of life results
from the trial also favoured the CAP-CRT arm (Hurt et al, 2015).
The RT Quality Assurance results from this trial have also been
previously reported (Fokas et al, 2015, 2016).
When the initial results were published previously, 46 of the 74
randomised patients had died. At the time of the analysis presented
in this manuscript 69 of the 74 randomised patients had died and
we have looked at the updated survival outcomes including
multivariable analysis of prognostic factors, patterns of failure, and
implications for future research.
MATERIALS AND METHODS
The trial design, treatment options, eligibility criteria, and follow-
up modalities were previously reported in detail (Mukherjee et al,
2013). In summary, the trial included patients with the following
key eligibility criteria: age418 years; histologically or cytologically
proven malignancy of the pancreas that was locally advanced, non-
metastatic, and inoperable (or operable but patient medically unfit
for surgery); tumour diameter p7 cm; WHO performance status
(PS) 0–2; adequate haematological, liver, and renal function.
Lymphoma or neuroendocrine tumours of the pancreas were
excluded. Following 12 weeks of induction, GEMCAP chemother-
apy (3 cycles: GEM 1000mgm 2 days 1, 8, 15; CAP 830mgm 2
days 1–21 q28 days), patients had a re-staging CT scan and those
with: responding or stable disease according to Response
Evaluation Criteria in Solid Tumours (RECIST) criteria (version
1.1); tumour diameterp6 cm; WHO PS 0–1; haematological, liver,
and renal function as for registration; and no greater than 10%
weight loss from that at baseline, were randomised (1 : 1 minimisa-
tion with a random element (80 : 20) stratified by recruiting
hospital, WHO PS (0 or 1) and disease location (head or body/
tail)) to receive a further cycle of GEMCAP followed by either CAP
(830mgm 2 b.d. on days of RT only) or GEM (300mgm 2
weekly) with radiation (50.4 Gy per 28 fractions with weekends
off). Prospective RT quality assurance was mandated (Fokas et al,
2016). The primary end-point was 9-month PFS. Secondary end
points included OS, local and distant PFS (LPFS and DPFS),
objective disease response, toxicity, treatment compliance, and
quality of life (EORTC C30 and PAN26). QOL, WHO PS, and
CA19.9 were collected at baseline, week 17 (just prior to
radiotherapy), week 26, 39, and 52, CT scans and RECIST
assessments were mandated at baseline, week 13 (prior to
randomisation), week 26, week 39, and week 52. Treatment
following progression was as per institutional practice and no
specific regimen was recommended. The trial was approved by a
UK multicentre ethics committee and individual informed consent
was obtained from all participants.
All statistical analyses were pre-planned and conducted using
Stata SE 14 (Stata Corporation, College Station, TX, USA). We
calculated survival from the date of registration to when an event
occurred, that is, progression and death from any cause for PFS,
and death from any cause for OS. Patients who were event free
were censored at the time they were last known to be event free.
We estimated event time distributions with the Kaplan–Meier
method and compared OS and PFS with HRs from Cox regression
in univariable models and multivariable models. Global health
status (GHS) from the EORTC C30 was included in the baseline
model as it has been found to be prognostic elsewhere (Quinten
et al, 2014). We tested the proportional hazards assumption of
each model with Cox–Snell residuals and Schoenfeld’s global test.
We conducted an updated analysis of OS and PFS using the mature
data in the intention-to-treat and per-protocol (patients starting
CRT) population both unadjusted and adjusted for the randomisa-
tion stratification variables. In addition, we used the above
methods to ascertain which variables were prognostic at two
separate points in the treatment pathway:
(i) Which baseline variables were prognostic of OS for all
registered including those patients who were not randomised?
This analysis used date of registration as the start of the time
period.
(ii) Which variables at the start of radiotherapy were prognostic
of OS and PFS? This per protocol analysis used date of start of
radiotherapy as the start of the time period.
In the multivariable models, we included all variables thought a
priori to have a prognostic effect and included recruitment centre
as a random frailty effect. In order to obtain cut-offs for CA19.9
that can be validated in future studies, ROC analysis was used with
12-month OS as the end point. We calculated HRs for GHS for
every 10-point difference in scores as has been done elsewhere
(Quinten et al, 2014) We did not adjust for multiplicity in these
primarily hypothesis generating analyses.
RESULTS
Study population. The study population was described in detail in
the first report (Mukherjee et al, 2013). Between 24 December 2009
and 25 October 2011, a total of 114 patients were registered into the
trial from 28 hospitals across the UK (Figure 1) and following
induction chemotherapy, 74 patients were eligible for randomisation
(CAP-CRT¼ 36; GEM-CRT¼ 38). Median age was 64.3 (IQR: 57.7–
70.3), 55.3% (n¼ 63) were male, the mean estimated longest
diameter of primary lesion was 4.2 cm (s.d.: 1.5), and WHO PS 0/
1/2 was 48.3% (n¼ 55), 44.7% (n¼ 51), 7.0% (n¼ 8), respectively.
Updated analysis in all registered patients. This population
consisted of the 114 registered patients. At the time of analysis, 105
of the 114 patients had died and the surviving 9 patients had been
followed up for a median of 10.9 months (IQR: 2.9–18.7).
Figure 2A shows the updated OS and PFS of this population.
Updated analysis in randomised patients. The intention to treat
analysis included the 74 randomised patients. At the time of
analysis, 34 out of 36 patients in the CAP-CRT arm and 35 out of
38 in the GEM-CRT arm had died. The surviving five patients had
been followed up for a median of 12.2 months (IQR: 7.5–41.9).
Figure 2B and C shows the updated OS and PFS. Median OS was
17.6 months (95% CI: 14.6–22.7) in the CAP-CRT arm and 14.6
months (95% CI: 11.1–16.0) in the GEM-CRT arm (HR: adjusted:
0.68 (95% CI: 0.38–1.21, P¼ 0.185); unadjusted: 0.73 (95% CI:
0.46–1.18, P¼ 0.203)). Median PFS was 12.0 months (95% CI:
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10.0–15.2) in the CAP-CRT arm and 10.4 months (95% CI: 8.8–12.7)
in the GEM-CRT arm (HR: adjusted: 0.60 (95% CI: 0.32–1.14,
P¼ 0.120); unadjusted: 0.73 (95% CI: 0.44–1.23, P¼ 0.244)).
Although both end points still favoured CAP-CRT, neither achieved
statistical significance in either unadjusted or adjusted models.
In a per protocol analysis that excluded the two randomised
patients who did not start chemo-radiotherapy (two patients in the
CAP-CRT due to disease progression), the adjusted and unadjusted
HRs for OS were 0.61 (95% CIs: 0.34–1.10, P¼ 0.101) and 0.69
(95% CIs: 0.43–1.12, P¼ 0.138), respectively and for PFS were 0.50
(95% CIs: 0.26–0.98, P¼ 0.043) and 0.67 (95% CIs: 0.40–1.14,
P¼ 0.143).
The primary end point, 9 months PFS, was highly predictive of
OS. The median OS in those who had progressed at 9 months was
11.3 (95% CI: 9.5–14.1) months compared to 20.7 (95% CI: 17.6–
24.6) months in those who had not progressed at that time point
(HR: 5.2, 95% CI: 1.5–5.6, Po0.001).
Baseline model. Upon ROC analysis, the optimum cut off for
baseline CA19.9 for predicting 12-month OS in the 101 registered
patients where both CA19.9 data and 12-month OS status were
available was found to be X613 IUml 1 (75% correctly classified
for 12-month OS, sensitivity¼ 69.8%, specificity¼ 79.6%) (Supple-
mentary Figure 1a).
Of the 114 patients registered into the trial, 8 had CA19.9
missing at baseline and 3 had estimated longest diameter of
primary lesion missing. A further 9 patients had EORTC C30 GHS
missing leaving 94 patients with full data for analysis of all the
baseline prognostic factors. Eighty seven of these patients had died
at the time of analysis. The surviving seven patients had been
followed up for a median of 10.9 months (IQR: 2.8–18.7) after
registration into the trial. Age X65 years, better performance
status, lower CA19.9 (o613 IU l 1), and shorter tumour diameter
(analysed as continuous variable) were significantly predictive of
improved OS in multivariable analysis (Table 1). The same
variables were significant in sensitivity analysis that excluded the
EORTC C30 GHS variable (n¼ 103). In a further sensitivity
analysis that also excluded baseline CA19.9 (n¼ 111), age becomes
non-significant.
Start of radiotherapy model—OS. Upon ROC analysis, the
optimum cut-off for pre-radiotherapy (week 17) CA19.9 for
predicting 12-month OS in the 56 randomised patients who started
radiotherapy and where both CA19.9 data and OS status at 12-month
were known was found to be X46 IUml 1 (71% correctly
classified for 12-month OS, sensitivity¼ 61.5%, specificity¼ 64.3%;
Supplementary Figure 1b). Proportional change in CA19.9 between
baseline and week 17 was less able to predict 12-month OS (area
under ROC curve¼ 0.6505, graph not shown).
Of the 74 patients randomised in SCALOP, 2 patients
progressed prior to the start of radiotherapy leaving 72 patients
in the per protocol analysis. CA19.9 at week 17 was missing in 14
patients, tumour volume measurement was missing in 2 patients,
and WHO performance status at week 17 was missing in 2
patients, leaving 54 patients with full data in the analysis. CAP-
CRT, age X65 years, better performance status (0 vs 1–2), and
lower CA19.9 (o46 IUml 1) were all found to be significantly
predictive of improved OS in multivariable analysis (Table 2). In a
sensitivity analysis, the multivariable analysis was repeated without
CA19.9 (which meant that 67 patients could be used); CAP-CRT
(P¼ 0.011), age X65 (P¼ 0.030), and better performance status
(0 vs 1–2) (P¼ 0.008) were all still significantly associated with
improved OS.
Start of radiotherapy model—PFS. CAP-CRT, age X65 years,
better performance status (0 vs 1–3), and lower CA19.9
(o46 IUml 1) were all found to be significantly predictive of
improved PFS in multivariable analysis (Table 2). In a sensitivity
analysis, the multivariable analysis was repeated without CA19.9
(as above, n¼ 67); CAP-CRT (P¼ 0.005), age X65 (P¼ 0.021),
and better performance status (P¼ 0.046) were still significantly
associated with improved PFS.
LPFS was not superior in the CAP-CRT arm in the multi-
variable model (n¼ 54; HR¼ 0.58; 95% CIs: 0.25–1.36; P¼ 0.207)
but was found to be superior in a sensitivity analysis that excluded
CA19.9 (n¼ 67; HR¼ 0.48; 95% CIs: 0.25–0.93; P¼ 0.030;
Figure 2D).
DPFS was superior in the CAP-CRT arm, both in a multi-
variable model (n¼ 54; HR¼ 0.24; 95% CIs: 0.10–0.58; P¼ 0.001)
and a sensitivity analysis that excluded CA19.9 (n¼ 67; HR¼ 0.36;
95% CIs: 0.19–0.68; P¼ 0.002; Figure 2E).
Patterns of progression in the 72 patients who started radio-
therapy are shown in Table 3. We performed a post hoc analysis
looking at the OS of those patients who progressed locally (n¼ 14,
median OS 12.7 months, 95% CIs: 10.8–20.1) compared to those
patients who had metastatic progression first (n¼ 22, median OS
10.3 months, 95% CIs: 7.4–15.2). We found that OS was
significantly worse in the metastatic group (HR¼ 2.7, 95% CIs:
Assessed for eligibility (n=216) 
Excluded (n=102) 
• Not meeting inclusion criteria (n=79) 
• Declined to participate (n=19) 
• Other reasons (n=4) 
Allocated to CAP-CRT (n=36) Allocated to GEM-CRT (n=38) 
Randomised (n=74) 
Registered (n=114) 
Excluded (n=40) 
• Progressed (n=15) 
• Clinician choice (intolerance/surgery required for 
complications/weight loss) (n=10) 
• Patient choice (n=9) 
• Death (n=5) 
• Should not have been registered (n=1) 
Figure 1. CONSORT flow diagram of trial participants.
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1.19–6.14, P¼ 0.018) in a Cox regression that included the other
covariates found to be significant in the model above (age, trial
arm, performance status).
DISCUSSION
The updated intention to treat analysis shows that the median
OS of both arms of the trial are better than initially reported, but
superior OS and PFS in the CAP-CRT arm is no longer
statistically significant. However, adjusted per protocol analysis
excluding patients who did not start CRT (due to progression)
did show superior PFS in the CAP-CRT arm. In addition,
multivariable per protocol analyses suggest that for those
patients who started radiotherapy, CAP-CRT is still associated
with statistically superior OS, PFS, and DPFS. Age X65 years,
better performance status (0 vs 1–3) and lower CA19.9 levels,
both at baseline and at start of CRT were also predictive of
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Figure 2. Kaplan–Meier curves of survival. (A) OS and PFS (all registered patients). Median OS: 12.6 months (95% CI: 11.3–14.9). Median PFS: 9.2
months (95% CI: 7.7–10.3). (B) OS by treatment arm (randomised patients). Median OS: CAP-CRT: 17.6 months (95% CI: 14.6–22.7). GEM-CRT:
14.6 months (95% CI: 11.1–16.0). HR: unadjusted: 0.73 (95% CI: 0.46–1.18, P¼ 0.203). Adjusted: 0.68 (95% CI: 0.38–1.21, P¼0.185). (C) PFS by
treatment arm (randomised patients). Median PFS: CAP-CRT: 12.0 months (95% CI: 10.0–15.2). GEM-CRT: 10.4 months (95% CI: 8.8–12.7). HR:
unadjusted: 0.73 (95% CI: 0.44–1.23, P¼ 0.244). Adjusted: 0.60 (95% CI: 0.32–1.14, P¼0.120). (D) LPFS by treatment arm (randomised patients).
(E) DPFS by treatment arm (randomised patients).
BRITISH JOURNAL OF CANCER Long-term results and recurrence patterns from SCALOP
4 www.bjcancer.com |DOI:10.1038/bjc.2017.95
improved outcomes; additionally, maximum tumour dimension
was found to be predictive at baseline. Nine-month PFS was
found to be highly predictive of OS. Following CRT, patients
who progressed with metastatic disease as first site of progression
had significantly worse survival than those who presented with
local progression.
Since the initial publication of SCALOP, the LAP07 study has
been published (Hammel et al, 2016). This trial had a 2 2
randomisation, included 449 patients and compared (1) che-
motherapy alone to chemotherapy followed by consolidation CRT
and (2) addition of erlotinib to standard gemcitabine induction
chemotherapy. The CAP-CRT used in the trial was similar to the
CAP-CRT arm of SCALOP. LAP07 showed inferior survival in the
erlotinib arm, and no benefit of adding CRT to single-modality
chemotherapy in terms of OS (15.2 vs 16.5 months, P¼ 0.83).
However local progression was significantly lower in the CRT arm
(46% vs 32%, P¼ 0.03) and treatment-free survival favoured CRT
(6.1 vs 3.7 months, P¼ 0.02). In addition, PFS approached
statistical significance in favour of CRT (8.4 vs 9.9 months,
P¼ 0.06). The median OS and the low rates of CRT-associated
toxicity seen in SCALOP mirror the findings from the LAP07
study providing external validation to likely survival outcomes
from induction chemotherapy followed by CAP-CRT. The survival
in SCALOP is comparable to outcomes in borderline-resectable
pancreatic cancer treated with neo-adjuvant therapy and surgery
(Assifi et al, 2011).
While debate continues over the role of CRT in LAPC, a CA19.9
cut-off of 46 IUml 1 showed modest specificity and sensitivity of
predicting patients who are likely to be alive at 12 months.
Although this cut-off requires external validation, such CA19.9
thresholds may help clinicians to decide whether or not to offer
CRT in any given patient who has completed induction
chemotherapy.
Both local failures (overall 33.3%) and metastatic failures
(44.5%) remain high, suggesting the need to optimise both
systemic and local components of the treatment and/or the need
for further (molecular) selection to confine the use of loco-
regional therapy to a smaller group of patients who are more
likely to have confined disease. The SCALOP2 trial aims to build
on SCALOP and will test the role of intensification of the CRT
regimen in patients treated with an effective induction che-
motherapy regimen. Nelfinavir is a protease inhibitor, which in
pre-clinical studies has been shown to reduce hypoxia and
improve vascularity. A small phase II study has shown promising
outcome from integrating nelfinavir in a pancreatic CRT
schedule (Wilson et al, 2016). SCALOP 2 is a multi-centre trial
in which 260 patients with LAPC will be registered to receive
gemcitabine and nab-paclitaxel induction chemotherapy—
patients with stable/responding disease will be randomised to
one of five arms: continuing gemcitabine-nab-paclitaxel che-
motherapy; conventional CRT (capecitabine with radiotherapy
50.4 Gy per 28 fractions); high-dose CRT (capecitabine with
radiotherapy 60 Gy per 30 fractions); conventional CRT with
nelfinavir; high-dose CRT with nelfinavir.
While designing the SCALOP trial, we chose the 9-month
PFS end point based on the time point that showed the
widest separation in survival curves in the original study by
Huguet et al (2007). We have now shown in a prospective
trial that 9-month PFS was highly predictive of OS (HR: 5.2,
95% CI: 1.5–5.6, Po0.001), which supports the use of this
end point in future phase II trials to allow earlier reporting of
results.
It is difficult to explain why age 465years was found to
be a favourable prognostic criteria. CRUK statistics (http://
www.cancerresearchuk.org/health-professional/cancer-statistics/
statistics-by-cancer-type/pancreatic-cancer/survival#heading-One) indi-
cate that increasing age is normally associated with poor survival
in pancreatic cancer. The numbers in this study are small and the
data need to be interpreted with caution, for example, age becomes
non-significant in the baseline model in a sensitivity analysis that
excluded variables with missing data. It should also be noted that
there is likely to be inherent bias for patient selection in clinical
trials and it is therefore possible that older patients who are fit
enough to be considered for SCALOP trial were a biologically
selected patient group with better prognosis.
A weakness of the study is the amount of missing data in the
models. Twenty out of the 114 patients in the baseline model and
18 out of the 72 patients in the start of radiotherapy model were
missing covariates. In the former model, this was primarily due to
missing EORTC C30 GHS and a number of the smaller centres not
being able to analyse for CA19.9; however our sensitivity analyses
that excluded these variables reached the same conclusions
(although age become non-significant for OS). In the latter model,
this was again primarily due to CA19.9; however our sensitivity
Table 1. Univariable and multivariable cox regression analysis of OS by baseline characteristics in all patients
OS (months)a Univariable Multivariable
n Median 95% CIs HR 95% CIs P HR 95% CIs P
Age
o65 52 11.7 9.8–14.6 1.00 1.00
X65 42 14.1 11.1–17.6 0.77 0.50–1.19 0.237 0.54 0.33–0.88 0.013
Sex
Male 51 13.9 11.3–16.5 1.00 1.00
Female 43 11.9 9.3–14.1 1.01 0.65–1.56 0.964 1.12 0.69–1.80 0.654
WHO performance status
0 45 16.5 12.7–21.5 1.00 1.00
1–2 49 11.1 8.1–12.7 2.05 1.32–3.17 0.001 2.09 1.24–3.52 0.006
CA19.9
o613 54 16.5 13.9–19.7 1.00 1.00
X613 40 9.7 7.6–10.7 3.38 2.11–5.43 o0.001 4.11 2.38–7.12 o0.001
Global heath statusb 0.97 0.89–1.06 0.549 0.95 0.85–1.06 0.395
Longest diameterc 1.12 0.97–1.29 0.131 1.28 1.08–1.51 0.005
aFrom registration into SCALOP trial prior to induction CT.
bHRs were calculated for every 10-point difference in scores.
cHRs calculated for every 1 cm increase.
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analyses excluded CA19.9 and reached the same broad conclusions
(other than for LPFS).
In summary, this mature analysis shows that radiosensitisation
with low-dose gemcitabine remains an inferior regimen, both in
terms of efficacy and toxicity, and cannot be recommended in
future CRT trials. However, only the per-protocol analysis was
significant perhaps reflecting the small size of the study. CA19.9
levels o46 IUml 1 after induction chemotherapy may define a
group of patients more likely to benefit from consolidation CRT—
however, this requires further validation. Futhermore, 9-month
PFS is well correlated with OS and could therefore a useful end
point in future phase II pancreatic CRT trials. Future trials need to
optimise both systemic and local components of treatment.
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Sex
Male 32 12.2 9.0–15.7 1.00 1.00
Female 22 10.3 7.3–13.6 1.03 0.58–1.84 0.910 0.51 0.19–1.37 0.183
WHO performance status at
week 17
0 18 12.2 9.0–17.7 1.00 1.00
1–3b 36 10.3 7.7–14.6 1.04 0.58–1.89 0.885 3.94 1.54–10.12 0.004
CA19.9 at week 17
o46 26 15.2 11.5–19.9 1.00 1.00
X46 28 9.0 6.4–10.8 3.58 1.89–6.78 0.000 5.66 1.72–18.70 0.004
Gross tumour volumec 1.00 0.99–1.01 0.672 0.99 0.97–1.01 0.233
PFS (months)a Univariable Multivariable
n Median 95% CIs HR 95% CIs P HR 95% CIs P
Trial arm
GEM 29 6.0 4.5–8.6 1.00 1.00
CAP 25 8.3 6.5–11.5 0.69 0.38–1.26 0.223 0.33 0.12–0.89 0.028
Age at start of radiotherapy
o65 24 5.6 4.1–8.3 1.00 1.00
X65 30 8.2 6.0–9.8 0.79 0.44–1.44 0.450 0.17 0.05–0.58 0.005
Tumour site
Head 46 7.0 5.2–9.8 1.00 1.00
Body/tail 8 8.3 4.1–N 0.79 0.33–1.89 0.598 0.69 0.14–3.42 0.645
Sex
Male 32 8.3 5.6–10.1 1.00 1.00
Female 22 6.4 5.0–7.7 1.84 0.97–3.48 0.062 1.87 0.61–5.67 0.271
WHO performance status
0 18 8.2 4.5–12.9 1.00 1.00
1–3b 36 7.6 5.3–9.8 1.10 0.57–2.12 0.777 3.04 1.10–8.35 0.031
CA19.9
o46 26 10.1 8.6–15.5 1.00 1.00
X46 28 5.2 4.4–9.7 4.62 2.29–9.29 0.000 9.31 2.25–38.5 0.002
Gross tumour volumec 1.00 0.99–1.01 0.560 0.99 0.97–1.01 0.414
aFrom first fraction of radiotherapy.
bOne patient was PS2 and one was PS3—these two patients deteriorated between randomisation at week 12 and at the start of radiotherapy at week 17.
cAs calculated by the investigator—HRs calculated for every 1 cc increase.
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Table 3. Patterns of disease progression at 12 months
CAP-CRT
(N¼34)
GEM-CRT
(N¼38)
All randomised
(N¼72)
n % n % n %
Alive and without
progression
1 2.9 1 2.6 2 2.8
Died before progression
detecteda
11 32.4 13 34.2 24 33.3
Progressed 22 64.7 23 60.5 46 63.9
Local 8 23.5 6 15.8 14 19.4
Metastatic 11 32.4 11 29.0 22 30.6
Both 3 8.8 7 18.4 10 13.9
aAll these patients died with pancreatic cancer as the primary or secondary cause.
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